First Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma

A Phase 1/2 clinical trial of FCX-013, Castle Creek Biosciences' experimental gene therapy for moderate to severe localized scleroderma, has dosed the first participant. The study (NCT03740724), which is expected to enroll up to 10 adults with localized scleroderma, or morphea, is still...